Objective-The purpose of this study was to examine the hypothesis that angiotensin II (Ang II) induced endothelial cyclooxygenase-2 (COX-2) expression, which in turn mediated the generation of proinflammatory cytokines. Methods and Results-Western blot analysis on primary rat endothelial cells showed Ang II induced COX-2 expression, which was abolished by cotreatment of p38 mitogen-activated protein kinase (SB 202190) and extracellular signal-regulated kinase 1/2 (PD 98059) inhibitors. Protein kinase C ␦ (PKC ␦ ) inhibitor (rottlerin) prevented extracellular signal-regulated kinase 1/2 phosphorylation and COX-2 expression. The pivotal role of PKC ␦ was further supported by a similar stimulatory effect of the PKC activator on COX-2 expression, signified by Ang II-stimulated translocation of PKC ␦ to the plasma membrane, and confirmed by PKC ␦ phosphorylation at Tyr311. Small interfering RNA targeting PKC ␦ diminished COX-2 expression, which was further abrogated by SB 202190. Human mesenteric arteries incubated with Ang II showed increased levels of endothelial COX-2 and monocyte chemoattractant protein-1; the former was inhibited by SB 202190 plus rottlerin, whereas the latter was prevented by COX-2 inhibitor. Conclusion-The present study pinpoints a novel role of PKC ␦ in Ang II-induced endothelial COX-2 upregulation and identifies a COX-2-dependent proatherosclerotic cytokine monocyte chemoattractant protein-1. The findings raise the possibility of curtailing endothelial COX-2 expression as a means of limiting or preventing vascular inflammation.
A ngiotensin II (Ang II), the most prominent vasoactive peptide in the renin-angiotensin system, causes vascular dysfunction through an exaggerated production of reactive oxygen species (ROS) and vascular hypercontractility through stimulation of Ang II type 1 receptor (AT 1 R). 1 Ang II is also a potent inducer of the expression of proinflammatory cytokines, such as tumor necrosis factor-␣, and adhesion molecules such as vascular cell adhesion molecule-1. [2] [3] [4] These factors are prerequisite for the initiation of atherosclerosis. In addition, Ang II activates matrix metalloproteinases, thereby promoting cell migration and adverse vascular remodeling. 5 Ang II is thus closely associated with diseases accompanied by vascular inflammation.
Cyclooxygenase-2 (COX-2) is minimally expressed in healthy vascular tissues, but it is highly inducible on stimulation by growth factors, proinflammatory cytokines, and bacterial toxins. 6 -8 A marked upregulation of COX-2 is reported in inflamed vascular tissues, 9 in vascular remodeling of wireinjured mouse femoral arteries, 10 and in human atherosclerotic plaques. 11, 12 The expression of COX-2, prostanoid synthases, and prostaglandin receptors are upregulated in blood mononuclear cells and plaques of patients with carotid atherosclerosis. 11 The plasma level of prostaglandin E 2 , known to activate matrix metalloproteinases, is augmented in patients with atherosclerosis. 11, 12 Recent studies have shown that nonsteroidal antiinflammatory drugs can reduce vascular inflammation 3 and that COX-2 inhibition is beneficial in decreasing adhesion molecule expression in cancer cell lines. 13 Both Ang II and COX-2 are associated with vascular inflammation and remodeling. However, it remains to be explored whether COX-2 could play a direct role as a downstream effector in mediating Ang II-induced vascular pathogenesis. The altered endothelial cell function is the key contributor to vascular inflammation. In the present study, we aimed to test the hypothesis that Ang II could induce COX-2 expression in endothelial cells, which in turn is related to generation of proinflammatory cytokines.
Methods
A Supplemental Methods section is available online at http://atvb.ahajournals.org.
Cell Culture and Treatment
Endothelial cells were freshly cultured from rat thoracic aortae. 14 The identity of the cells was confirmed by positive staining for an endothelial cell-specific marker, platelet endothelial cell adhesion molecule-1 (Supplemental Figure I) . On confluence, cells were serum deprived for 24 hours and incubated with Ang II (100 nmol/L) for 8 hours unless otherwise stated. When used, inhibitors were preincubated with the cells for 30 minutes before the addition of Ang II.
Western Blot Analysis and Reverse Transcription-Polymerase Chain Reaction
Protein expressions and phosphorylation levels of COX-2, COX-1, p38 mitogen-activated protein kinase (MAPK), extracellular signalregulated kinase 1/2 (ERK1/2), and protein kinase C (PKC) isoforms were determined by Western blotting. COX-2 mRNA stabilization was examined by reverse transcription-polymerase chain reaction.
Cellular Protein Fractionation for Translocation Study of PKC Isoforms
Endothelial cells were incubated with 100 nmol/L Ang II for 1 minute and quickly cooled on ice to quench cellular reactions. Cytosolic and membranous proteins were extracted with the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem). Nuclear proteins were extracted with custom-made high-salt buffer. Equal amount of proteins were subjected to SDS-PAGE.
PKC ␦ Knockdown With Small Interfering RNA
Cells were transfected with either scramble siRNA or predesigned specific small interfering RNA (siRNA) targeting PKC ␦ transcripts to detect COX-2 expression after Ang II stimulation.
Suspension Antibody Array-Based Multiplex Immunoassay
Conditioned medium from endothelial cells treated with Ang II (100 nmol/L) for 24 hours were harvested, and the levels of interleukin-6, tumor necrosis factor-␣ and monocyte chemoattractant protein-1 (MCP-1) were measured with MILLIPLEX MAP rodent cytokine/ chemokine panel (Millipore) using the Bio-plex Suspension Array System (Bio-Rad), according to the manufacturers' instructions.
Ang II Infusion in Rats
Sprague-Dawley rats were infused with Ang II at 0.7 mg/kg per day or vehicle (normal saline) for 9 days using an osmotic pump. Aortae and renal arteries were preserved for immunohistochemical staining. Interlobal renal arteries were used for functional evaluation of endothelium-dependent relaxations.
Tissue Culture of Human Small Mesenteric Arteries
Human small mesenteric arteries were treated with Ang II (1 mol/L) for 24 hours in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin at 37°C. Arteries were preserved for cryosectioning and immunofluorescence localization of COX-2 and MCP-1.
Immunohistochemical Staining and Immunofluorescence Localization
Localization of COX-2 in the aortae and renal arteries from Ang II-infused rats was determined by immunohistochemistry. Human small mesenteric arteries harvested after a 24-hour incubation protocol were preserved for immunofluorescence to detect COX-2 and MCP-1 expression.
Functional Examination With Myography
Endothelium-dependent relaxations of the interlobal renal arteries from Ang II-infused rats were determined in myographs.
ROS Detection With Dihydroethidium Fluorescence
Production of intracellular ROS was measured with dihydroethidium (Molecular Probes).
Data Analysis
Results represent meansϮSEM of 5 to 6 separate experiments. Statistical significance was determined by 2-tailed Student t test or 1-way ANOVA followed by Bonferroni post tests when more than 2 treatments were compared (GraphPad Software, San Diego, CA). A probability value of less than 0.05 was regarded as statistically different.
Results

Ang II Induces COX-2 Expression in Endothelial Cells
COX-2 expression was undetectable in the untreated quiescent endothelial cells and was not induced by culturing in serum-deprived medium. Ang II at 100 nmol/L increased COX-2 expression, reaching a maximum after an 8-hour incubation, and this effect was concentration dependent (3 to 100 nmol/L) (Supplemental Figure IIA Of the 3 well-known kinase pathways, only p38 MAPK inhibitor (SB 202190, 10 mol/L) and ERK1/2 inhibitor (PD 98059, 20 mol/L) reduced Ang II-induced COX-2 expression, each by Ϸ50%, whereas SP 600125 (10 mol/L), a c-Jun-N-terminal kinase inhibitor, had no effect. Cotreatment with SB 202190 and PD 98059 produced additive inhibition ( Figure 1A) , suggesting a parallel involvement of p38 MAPK and ERK1/2 in mediating Ang II-induced COX-2 expression. By contrast, these inhibitors did not alter the expression of COX-1 (Supplemental Figure IIID) .
When the time course of ERK1/2 and p38 MAPK activation by Ang II was examined, peak phosphorylation of both kinases was noted Ϸ5 minutes after the addition of 100 nmol/L Ang II ( Figure 1B and 1C) .
PKC Activation Is Upstream of ERK1/2 in COX-2 Induction
Treatment with GF 109203X (GFX, 2 mol/L), an inhibitor for a broad spectrum of PKC isoforms, markedly reduced Ang II-induced COX-2 expression. Rottlerin (PKC ␦ inhibitor, 10 mol/L) but not Go 6976 (PKC ␣/␤ inhibitor, 1 mol/L) inhibited COX-2 expression ( Figure 1D ). These inhibitors did not affect COX-1 expression (Supplemental Figure IIIE) .
Next, the sequence of events involving PKC, ERK1/2, and p38 MAPK on Ang II stimulation was determined. PKC inhibition would be expected to prevent the activation of ERK1/2 and p38 MAPK if PKC is the upstream regulator of the 2 latter pathways. ERK1/2 phosphorylation was inhibited by GFX and rottlerin but not Go 6976, with PD 98059 serving as a positive control for ERK1/2 inhibition ( Figure 1E ). By contrast, p38 MAPK phosphorylation was prevented by losartan but unaltered by GFX, Go 6976, and rottlerin ( Figure 1F ), indicating that unlike ERK1/2, activation of p38 MAPK was independent of PKC ␦ regulation.
Reverse transcription-polymerase chain reaction on cells preexposed to Ang II for 4 hours and then treated with actinomycin-D revealed the participation of these kinases in maintaining COX-2 mRNA stability. Posttreatments with either SB 202190, PD 98059, or rottlerin partially reduced COX-2 mRNA levels, whereas the combined treatments of SB 202190ϩPD 98059 and SB 202190ϩrottlerin did not result in synergistic reduction in the levels of transcribed COX-2 mRNA (Supplemental Figure IID) , implying that unlike induction, these kinases may act in series to maintain COX-2 mRNA stability posttranscriptionally.
PKC ␦ Plays a Key Role With Little Involvement of Other PKC Isoforms
Studies with the pharmacological inhibitor of PKC ␦ , rottlerin, implied the participation of PKC ␦ in Ang II-induced COX-2 expression. To confirm the involvement of PKC ␦ , a time-dependent phosphorylation of PKC ␦ at the activation sites was determined. PKC ␦ was phosphorylated at Tyr311 in less than 1 minute after the addition of Ang II ( Figure 2A ). In contrast, residues Thr505 and Tyr332 were found to be nonphosphorylated throughout the 1-hour time course studied (Supplemental Figure IV) .
Cytoplasm to membrane translocation of various PKC isoforms was examined by fractionating the cytosolic and membranous portion of total protein from endothelial cells. This method was validated by a clear detection of large amount of cytosolic GAPDH in the cytosol but a minimal amount in the membranous fraction, and vice versa for membrane-bound NOX-2 subunit of NADPH oxidase (Supplemental Figure VA and VB). The results showed that PKC ␦ and PKC were activated on 1-minute stimulation with Ang II, which was signified by their increased levels in membranous fractions. By contrast, ␣, , and isoforms were not increased in the membranous portions of Ang II-stimulated cells compared with that of control. PKC was minimally expressed in endothelial cells ( Figure 2B , Supplemental Figure V ). PKC ␦ translocation was abolished by losartan ( Figure 2C ). SB 202190 and PD 98059 failed to inhibit Ang II-induced PKC ␦ translocation (Supplemental Figure VE) , again confirming the notion that ERK1/2 can only be a downstream target of PKC ␦ , but not vice versa, whereas p38 MAPK and PKC ␦ are independent of each other. Notably, PKC ␦ translocation from cytosol to nucleus was The inducible role of PKC ␦ in COX-2 expression was also pinpointed using an exogenous PKC activator, phorbol 12-myristate 13-acetate (PMA). PMA at 1 mol/L time-dependently increased COX-2 expression, whereas its negative analog, 4␣-PMA, had no effect ( Figure 2E , Supplemental Figure VIIIE) . Such increase in COX-2 expression was again sensitive to inhibition by GFX and rottlerin but not Go 6976 ( Figure 2E , Supplemental Figure VIIIF) .
Ang II-Induced Release of MCP-1 Is COX-2 Dependent
The level of MCP-1 in the conditioned medium from endothelial cells treated with 100 nmol/L Ang II for 24 hours increased (Figure 3 ), whereas the release of interleukin-6 and tumor necrosis factor-␣ fell below detectable levels (data not shown). The MCP-1 release was inhibited by losartan and 2 structurally different COX-2 inhibitors, celecoxib and NS 398 (both at 3 mol/L) ( Figure 3 ).
Renovascular Dysfunction and Elevated Endothelial COX-2 Expression in Ang II-Infused Rats
Systolic blood pressure of rats rose from 104.3Ϯ4.6 to 174.0Ϯ9.6 mm Hg during a 9-day period of Ang II infusion, and this increase was prevented by concomitant oral treatment with losartan ( Figure 4A ). Endothelium-dependent relaxations were impaired in interlobal renal arteries from the Ang II-infused rats, and this impairment was abolished by losartan treatment ( Figure 4B ). The attenuated relaxations were restored by acute treatment with the COX-2 inhibitor celecoxib (3 mol/L) ( Figure 4C ) but not by the COX-1 inhibitor sc-560 (data not shown). Immunohistochemical staining revealed that endothelial COX-2 expression ( Figure  4D and 4E, arrows) was augmented in both aortae and renal arteries of Ang II-infused rats, and the increased COX-2 staining was attenuated by losartan.
Ang II-Induced COX-2 Expression and COX-2-Dependent MCP-1 Expression in Human Mesenteric Arteries
Ang II-induced expression of proinflammatory MCP-1 was also demonstrated in the endothelial layer of human mesenteric arteries. The left columns of Figure 5A and 5B show the green autofluorescence from elastin of the internal elastic lamina, which delineated the artery into endothelial and smooth muscle layers. The middle columns feature the fluorescence emitted from Alexa Fluor 546 -conjugated secondary antibodies, which were tagged to primary antibodies against either COX-2 ( Figure 5A ) or MCP-1 ( Figure 5B ), appearing in reddish orange together with the noise from autofluorescence. In the overlay images in the right column, the autofluorescence and noise are yellowish green, and the remaining reddish orange signifies the signals from COX-2 or MCP-1. Referring to the right column of Figure 5A , endothelial COX-2 expression was remarkably augmented after a 24-hour exposure to Ang II (1 mol/L); expression was prevented by cotreatment with SB 202190 and rottlerin but remained unaffected in solvent control exposed to dimethyl sulfoxide. It is noteworthy that this COX-2 expression may contribute to the MCP-1 expression, as evidenced by an increase of endothelial MCP-1 expression in the same arteries treated with Ang II, which was inhibited by preincubation with celecoxib but not the solvent dimethyl sulfoxide ( Figure 5B ).
ROS Do Not Mediate COX-2 Upregulation
Dihydroethidium fluorescence in endothelial cells showed that the ROS level rose Ϸ2-fold in Ϸ30 s after Ang II addition, which was inhibited by losartan, the NADPH oxidase inhibitor apocynin (100 mol/L), and ROS scavengers, tiron (1 mmol/L) plus diethyldithiocarbamate (100 mol/L) (Supplemental Figures IX and XA) . Inhibitors of ROS-producing enzymes, including apocynin (100 mol/ L), oxypurinol (xanthine oxidase inhibitor, 100 mol/L), 2-amino-5,6-dihydro-6-methyl-4H-1,3-thiazine hydrochloride (inducible nitric oxide synthase inhibitor, 30 mol/L), N G -nitro-L-arginine methyl ester (nonspecific nitric oxide synthase inhibitor, 100 mol/L), the ROS scavengers tempol, and tiron plus diethyldithiocarbamate, however, did not decrease the Ang II-induced COX-2 expression (Supplemental Figure XB) , thus ruling out the participation from ROS. Indeed, exogenous H 2 O 2 induced only a small increase (Ϸ3-fold) in COX-2 expression compared with the marked stimulation (Ͼ15-fold) by Ang II (Supplemental Figure XC) .
Discussion
The present study provides novel insights on the molecular mechanism and sequence of intracellular events on the upregulation of endothelial COX-2 expression by Ang II, pinpointing a novel role of PKC ␦ activated at Tyr311 and joint contributions of ERK1/2 and p38 MAPK. We also defined the Ang II-induced release or expression of the COX-2-dependent proatherosclerotic cytokine MCP-1. The present results were first obtained from primary culture of rat endothelial cells, but they were also confirmed in an in vivo animal model of Ang II-infused hypertensive rats and extended to tissue culture of human arteries.
Ang II, a potent vasoconstrictive peptide, plays a central role in vascular dysfunction associated with hypertension and diabetes, and AT 1 R blockers represent a major class of antihypertensive drugs that interrupt Ang II-initiated intracellular signaling. 15 Although Ang II serves as a powerful ligand to trigger transcriptions of proatherosclerotic cytokines, 2-4 the role of the highly inducible proinflammatory enzyme COX-2 in vascular diseases has recently gained attention, as its overexpression is also detected in human atherosclerotic plaques. 11 However, the relationship between Ang II and COX-2 remains elusive as to whether COX-2 acts as a direct downstream effector of Ang II to mediate vascular inflammation, especially in endothelial cells, which represent the first-line initiation point of atherosclerosis. The present study demonstrated that Ang II could markedly upregulate COX-2 expression in endothelial cells through AT 1 R activation, agreeing with the preliminary findings of Kramer et al using Northern blot analysis. 16 The COX-2 expression was jointly mediated by p38 MAPK-and ERK1/2-dependent signaling pathways, as the inhibitor of either kinase, SB 202190 or PD 98059, could only partially suppress the COX-2 expression, whereas their cotreatment resulted in additive inhibition that almost abolished COX-2 expression. It appeared that c-Jun-Nterminal kinase was unlikely to be involved, as its inhibitor did not alter Ang II-induced COX-2 expression.
Because p38 MAPK and ERK1/2 are sensitive to redox triggers, [17] [18] [19] we initially suspected that Ang II-induced oxidative stress might contribute to COX-2 expression. This possibility, however, was excluded by 2 observations. First, Ang II-stimulated ROS production was prevented by the NADPH oxidase inhibitor apocynin and by the ROS scavenger tiron plus diethyldithiocarbamate; however, Ang II-induced COX-2 expression was unaltered by these inhibitors and by inhibitors against xanthine oxidase, inducible nitric oxide synthase, and nitric oxide synthase uncoupling. Second, H 2 O 2 , which was reported to increase COX-2 expression in human umbilical vein endothelial cells, 20 induced a mild increase in COX-2 expression compared with that stimulated by Ang II. Our results differ from a previous study showing that in human saphenous vein endothelial cells, interleukin-1␣-induced COX-2 expression involves both NADPH oxidase-derived superoxide anion and H 2 O 2 . 21 Indeed, our recent findings on bone morphogenic protein-4 -induced COX-2 expression also showed that the kinase mediator p38 MAPK is activated by bone morphogenic protein-4 -stimulated NADPH oxidase-derived ROS. 22 Our further experimentation, aimed at understanding why oxidative stress is involved in bone morphogenic protein-4 -induced COX-2 induction but not that stimulated by Ang II, showed that bone morphogenic protein-4 (20 ng/mL) induced a significantly higher ROS level compared with Ang II at 100 nmol/L (the concentration used in the cell-based studies) or even 1 mol/L (Supplemental Figure XI) , implying that the level of oxidative stress induced by the agonist is an important determinant in whether the redox-sensitive kinases are turned on by the radicals and hence whether there is a role for the ROS to mediate COX-2 upregulation. The MAPKs are not preferentially activated by the Ang II-induced ROS, possibly owing to the ineffective ROS level. Alternatively, the source and production site of ROS or type of ROS produced may play differential roles in both induction of COX-2 expression and stimulation of COX-2 activity. These need further investigation at subcellular levels. PKC appears to be another possible upstream target because PKC is associated with the G-protein-coupled AT 1 R. Herein we defined a novel role of PKC ␦ , activated at Tyr311, to mediate COX-2 expression in Ang II-treated rat aortic endothelial cells. To our surprise, PKC ␦ is not phosphorylated at the activation loop of residue Thr505 in response to Ang II. As pointed out by Liu et al, phosphorylation of the activation loop may not be necessary for PKC ␦ activation and that PKC ␦ -mediated apoptosis of HEK293T cells does not require phosphorylation at the activation loop. 23 Indeed, earlier reports also found that mutant PKC ␦ with activation loop dephosphorylated was still in full activity. 24 -26 As to the tyrosine residues, Tyr311 but not Tyr332 was phosphorylated by Ang II, although both are concomitantly phosphorylated in response to oxidative stress such as H 2 O 2 . 27 As explained by Rybin et al, the agonist (Ang II or PMA)-dependent selective phosphorylation of tyrosine residues may possibly be effected via the selective Tyr311 kinase c-Abl, whereas other kinases (sensitive to redox changes) may cause a concurrent phosphorylation in both residues. 27 Although we cannot detail all the phosphorylation residues that are involved in the activation of PKC ␦ in response to Ang II (because of a large number of possible phosphorylation sites and the complex regulation of PKC ␦ ), our present data suggest that at least Tyr311 is phosphorylated to mediate Ang II-induced PKC ␦ activation, without the possible involvement of residues Thr505 and Tyr332.
Pharmacologically, Ang II-induced COX-2 expression and PMA (PKC activator)-induced COX-2 expression were both sensitive to inhibition by GFX (a broad spectrum of PKC inhibitor) and rottlerin (PKC ␦ inhibitor). Of note, GFX and rottlerin also inhibited Ang II-induced ERK1/2 phosphorylation, indicating that PKC ␦ is likely the upstream activator of ERK1/2. Activation of p38 MAPK was likely independent of PKC regulation because its phosphorylation was unaffected by PKC inhibitors. Interestingly, posttreatments of these kinase inhibitors along with actinomycin-D in cells preexposed to Ang II demonstrated a partial reduction in Ang II-induced COX-2 mRNA levels, indicating that p38 MAPK, ERK1/2, and PKC ␦ may also help to stabilize the COX-2 mRNA transcribed. In contrast to the results from Western blot analysis in which cotreatments of SB 202190ϩPD 98059 and SB 202190ϩrottlerin produced clear additive effect that totally abolished Ang II-induced COX-2 expression, neither SB 202190ϩPD 98059 nor SB 202190ϩrot-tlerin showed a significant synergistic suppression on the COX-2 mRNA level, implying that the kinases may function in series in preserving mRNA stability, which is different from COX-2 induction, when they act jointly. Doller et al recently demonstrated in rat mesangial cells that PKC ␦ take a critical role in shuttling the mRNA-stabilizing factor human antigen R and thereby posttranscriptionally maintaining COX-2 expression induced by Ang II. 28 Of note, members of MAPK family can also interact with human antigen R to stabilize the mRNA coding for inflammatory mediators such as tumor necrosis factor-␣ and COX-2. 29, 30 Ang II-induced COX-2 expression in vascular smooth muscles is reported to be mediated by p38 MAPKand ERK1/2-mediated mRNA stabilization of COX-2 mRNA. 31 Nonetheless, taken together with the results from exogenous PKC activator PMA which can induce rottlerin-sensitive COX-2 expression, Ang II-stimulated activation of PKC ␦ and the MAPKs possibly cause an upregulation of COX-2 expression by both transcription induction and mRNA stabilization.
To address the concern over the specificity of pharmacological inhibitors used, we studied the treatment-induced translocation of PKC ␦ from the cytoplasm to the plasma membrane and excluded the participation of other PKC isoforms. Translocation of soluble cytosolic PKC to the particulated membranous form is a key feature that signifies PKC activation. 32 Comparing the portion of membranous PKC after Ang II stimulation with that of control, only PKC ␦ and PKC were found to be responsive to Ang II. While PKC ␣ was activated by PMA but not Ang II, PKC and PKC remained unresponsive to either treatments, and PKC was not expressed in endothelial cells. Indeed, although PKC ␣ was activated by PMA, treatments with the PKC ␣/␤ inhibitor Go 6976 failed to suppress the PMA-induced COX-2 expression, thus contrasting a complete abrogation by rottlerin. Likewise, Ang II activated both PKC ␦ and PKC , yet the role of PKC in mediating COX-2 expression appears to be negligible, as indicated by the following 2 observations. First, PKC inhibitor V1-2 did not affect Ang II-induced COX-2 expression. Second, siPKC ␦ markedly suppressed COX-2 expression without affecting PKC expression. If PKC were to be significantly involved in mediating Ang II action, its nonsuppressed levels in siPKC ␦ -transfected cells with or without concomitant exposure to the p38 MAPK inhibitor SB 202190 would have maintained the inducible response of COX-2 expression as in the control or scramble siRNA-transfected cells. Taken together, these data indicate that even a number of PKC isoforms might be activated by Ang II PKC ␦ is probably the main isoform that is essentially coupled with endothelial COX-2 expression. It is noteworthy that inhibition of p38 MAPK by SB 202190 in combination with PKC ␦ knockdown cells prevented the induction of COX-2 expression, thus proving a parallel involvement of the PKC ␦ -ERK1/2 and p38 MAPK pathways. Such findings are in contrast to Ang II-induced COX-2 upregulation in vascular smooth muscle cells, which depends mainly on the ERK1/2 activity without the participation of PKC or p38 MAPK. 7 Pretreatment by inhibitor of either ERK1/2 or p38 MAPK did not affect Ang II-induced PKC ␦ translocation, again confirming that PKC ␦ is upstream of ERK1/2 activation and independent of p38 MAPK regulation. Although PKC ␦ can also move into the nucleus from the cytosol, 33 our present results showed that PKC ␦ is not translocated into the nucleus shortly (Ϸ1 minute) after Ang II exposure, in contrast to its clear and rapid particulation at the plasma membrane. Indeed, PKC ␦ was found to be imported into the nucleus at least 30 minutes after Ang II stimulation. 28 Our present data thus suggest that PKC ␦ , shortly after Ang II stimulation, first translocates to the membrane where it exerts its major effect on COX-2 induction via regulation of ERK1/2 activity. COX-2 mRNA stabilization by PKC ␦ may occur as a consecutive event following its delayed translocation into the nucleus.
Upregulation of endothelial COX-2 by Ang II could be demonstrated not only in cultured cells. Indeed, our study clearly showed an augmentation of endothelial COX-2 protein expression in the aorta and renal arteries of Ang II-infused rats, which was inhibited by concomitant oral treatment of losartan. Impairment of endothelium-dependent relaxations was acutely restored by the COX-2 inhibitor celecoxib, indicating that COX-2-derived vasoconstrictive prostanoids may contribute to vascular dysfunctions, as documented in diabetic, hypertensive, and aging animal models. 34 -36 Tissue culture experiments on human mesenteric arteries substantiate the findings in cultured rat endothelial cells. Ang II-induced endothelial COX-2 expression was prevented by cotreatment of SB 202190 and rottlerin. More importantly, increased COX-2 expression was accompanied by a concomitant rise in MCP-1 expression, with both proteins being immunolocalized to the endothelium. This MCP-1 increase was sensitive to COX-2 inhibition by celecoxib, clearly suggesting a causal relationship between these 2 proinflammatory and proatherosclerotic cytokines. Indeed, Ang II-induced MCP-1 release into the conditioned medium of cultured rat endothelial cells was also prevented by the 2 specific COX-2 inhibitors celecoxib and NS 398. Taken together, endothelial COX-2-dependent release of MCP-1 may represent a new concept in our understanding of the Ang II-induced vascular inflammation and atherosclerotic plaque formation involving macrophages. Which of the COX-2-derived prostanoids may mediate MCP-1 release warrants further investigation.
Assembling the time course of maximal activation of signaling proteins, and studies using pharmacological inhibitors and siRNA, we propose the following cellular pathways of Ang II-induced endothelial COX-2 expression (Figure 6 ). Ang II stimulates AT 1 R to activate PKC ␦ in Ͻ1 minute and subsequently ERK1/2 in Ϸ5 minutes, along with maximal PKCindependent p38 MAPK activation in Ϸ5 minutes. COX-2 expression was effected via induction and mRNA stabilization; it was detected at 1 hour and reached the maximum at 8 hours. MCP-1 release detected at 24 hours was COX-2 dependent. In view of the controversy regarding the use of COX-2 inhibitors Figure 6 . Postulated cellular mechanisms on Ang II-induced COX-2 expression in endothelial cells and time course of events. Ang II acts on AT 1 R, which then activates PKC ␦ in Ͻ1 minute. Activations of PKC ␦ -dependent ERK1/2 and PKC ␦ -independent p38 MAPK occur at Ϸ5 minutes. COX-2 begins to be expressed at Ϸ1 hour via induction and mRNA stabilization, and the expression reaches a maximum at Ϸ8 hours. COX-2-dependent MCP-1 release was detected in 24 hours.
and considering that PKC ␦ is preferentially activated in hyperglycemia and diabetes (detailed in Significance of Study in the online Supplement), the present study may suggest PKC ␦ as a more promising target for therapeutic intervention in COX-2-mediated vascular complications.
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